Mustafa Khasraw Mbchb,, Fracp, Frcp

List of Publications by Year
in descending order

195 papers	7,315 citations	101543 36 h-index	66911 78 g-index
211 all docs	211 docs citations	211 times ranked	10714 citing authors

#	Article	IF	Citations
1	Palbociclib in Hormone-Receptorâ€“Positive Advanced Breast Cancer. New England Journal of Medicine, 2015, 373, 209-219.	27.0	1,239
2	Management of glioblastoma: State of the art and future directions. Ca-A Cancer Journal for Clinicians, 2020, 70, 299-312.	329.8	969
3	High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Annals of Oncology, 2021, 32, 661-672.	1.2	586
4	Longitudinal molecular trajectories of diffuse glioma in adults. Nature, 2019, 576, 112-120.	27.8	320
5	Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?. Clinical Cancer Research, 2021, 27, 1236-1241.	7.0	222
6	Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance. Theranostics, 2017, 7, 1149-1158.	10.0	201
7	Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE. Clinical Cancer Research, 2018, 24, 737-743.	7.0	154
8	Epirubicin: Is it like doxorubicin in breast cancer? A clinical review. Breast, 2012, 21, 142-149.	2.2	151
9	Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial. Neuro-Oncology, 2023, 25, 123-134.	1.2	150
10	Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium. Neuro-Oncology, 2018, 20, 873-884.	1.2	119
11	Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro-Oncology, 2016, 18, 1357-1366.	1.2	116
12	Advances in the Treatment of Malignant Gliomas. Current Oncology Reports, 2010, 12, 26-33.	4.0	107
13	MYCN amplification drives an aggressive form of spinal ependymoma. Acta Neuropathologica, 2019, 138, 1075-1089.	7.7	104
14	PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?. Clinical Cancer Research, 2020, 26, 5287-5296.	7.0	88
15	Paraneoplastic Syndromes Affecting the Nervous System. , 2012, , 1388-1394.		87
16	Antiangiogenic therapy for high-grade glioma. The Cochrane Library, 2014, , CD008218.	2.8	84
17	EpCAM Aptamer-mediated Survivin Silencing Sensitized Cancer Stem Cells to Doxorubicin in a Breast Cancer Model. Theranostics, 2015, 5, 1456-1472.	10.0	84
18	Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. Neuro-Oncology, 2013, 15, 242-250.	1.2	83

#	Article	IF	Citations
19	Anti-angiogenic therapy for high-grade glioma. The Cochrane Library, 2018, 2018, CD008218.	2.8	81
20	Machine-learning prediction of cancer survival: a retrospective study using electronic administrative records and a cancer registry. BMJ Open, 2014, 4, e004007.	1.9	80
21	Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy. Nature Communications, 2021, 12, 352.	12.8	77
22	Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. Clinical Cancer Research, 2022, 28, 594-602.	7.0	67
23	Neurological complications of systemic cancer. Lancet Neurology, The, 2010, 9, 1214-1227.	10.2	64
24	Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience. Annals of Oncology, 2012, 23, 458-463.	1.2	63
25	Combination of palbociclib and radiotherapy for glioblastoma. Cell Death Discovery, 2017, 3, 17033.	4.7	62
26	Risk of metachronous breast cancer after BRCA mutationâ€“associated ovarian cancer. Cancer, 2013, 119, 1344-1348.	4.1	58
27	Outcomes after second surgery for recurrent glioblastoma: a retrospective caseâ€“control study. Journal of Neuro-Oncology, 2018, 137, 409-415.	2.9	53
28	Adapting to a Pandemic â€” Conducting Oncology Trials during the SARS-CoV-2 Pandemic. Clinical Cancer Research, 2020, 26, 3100-3103.	7.0	53
29	Leveraging external data in the design and analysis of clinical trials in neuro-oncology. Lancet Oncology, The, 2021, 22, e456-e465.	10.7	53
30	Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. Annals of Oncology, 2010, 21, 1302-1307.	1.2	52
31	Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study. Journal of Clinical Oncology, 2016, 34, 2258-2264.	1.6	52
32	The Paradoxical Effects of COVID-19 on Cancer Care: Current Context and Potential Lasting Impacts. Clinical Cancer Research, 2020, 26, 5809-5813.	7.0	44
33	A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylatedMGMTglioblastoma: the VERTU study. Neuro-Oncology, 2021, 23, 1736-1749.	1.2	44
34	Bevacizumab for the treatment of high-grade glioma: an update after Phase III trials. Expert Opinion on Biological Therapy, 2014, 14, 729-740.	3.1	41
35	Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. , 2021, 9, e002459.		41
36	Using lithium as a neuroprotective agent in patients with cancer. BMC Medicine, 2012, 10, 131.	5.5	39

#	Article	IF	Citations
37	CDK4/6 inhibitors in breast cancer. Anti-Cancer Drugs, 2015, 26, 797-806.	1.4	38
38	Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial. Journal of Neuro-Oncology, 2016, 128, 163-171.	2.9	38
39	Long-term use of temozolomide: Could you use temozolomide safely for life in gliomas?. Journal of Clinical Neuroscience, 2009, 16, 854-855.	1.5	37
40	Small bowel video capsule endoscopy: an overview. Expert Review of Gastroenterology and Hepatology, 2013, 7, 323-329.	3.0	37
41	Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours. Neuroendocrinology, 2018, 107, 237-245.	2.5	37
42	Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma. Journal of Translational Medicine, 2017, 15, 61.	4.4	34
43	Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF). Scientific Reports, 2019, 9, 2905.	3.3	34
44	The Need to Examine Metastatic Tissue at the Time of Progression of Breast Cancer: Is Re-biopsy a Necessity or a Luxury?. Current Oncology Reports, 2011, 13, 17-25.	4.0	32
45	Profiles of brain metastases: Prioritization of therapeutic targets. International Journal of Cancer, 2018, 143, 3019-3026.	5.1	31
46	The evolutionary pattern of mutations in glioblastoma reveals therapy-mediated selection. Oncotarget, 2018, 9, 7844-7858.	1.8	29
47	Late neurocognitive decline after radiotherapy for low-grade glioma. Nature Reviews Neurology, 2009, 5, 646-647.	10.1	27
48	Immune Checkpoint Inhibitors in Gliomas. Current Oncology Reports, 2017, 19, 23.	4.0	27
49	Anticonvulsant prophylaxis and steroid use in adults with metastatic brain tumors: summary of SNO and ASCO endorsement of the Congress of Neurological Surgeons guidelines*. Neuro-Oncology, 2019, 21, 424-427.	1.2	27
50	Emerging pharmacotherapy for cancer patients with cognitive dysfunction. BMC Neurology, 2013, 13, 153.	1.8	25
51	Survival Outcomes of Elderly Patients With Glioblastoma Multiforme in Their 75th Year or Older Treated With Adjuvant Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 98, 802-810.	0.8	25
52	Bevacizumab for the treatment of high-grade glioma. Expert Opinion on Biological Therapy, 2012, 12, 1101-1111.	3.1	23
53	Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors. , 2021, 9, e002015.		23
54	Management of Advanced Neuroendocrine Tumors With Hepatic Metastasis. Journal of Clinical Gastroenterology, 2009, 43, 838-847.	2.2	22

#	Article	IF	Citations
55	Utilizing 18F-fluoroethyltyrosine (FET) positron emission tomography (PET) to define suspected nonenhancing tumor for radiation therapy planning of glioblastoma. Practical Radiation Oncology, 2018, 8, 230-238.	2.1	22
56	Anticonvulsant Prophylaxis and Steroid Use in Adults With Metastatic Brain Tumors: ASCO and SNO Endorsement of the Congress of Neurological Surgeons Guidelines. Journal of Clinical Oncology, 2019, 37, 1130-1135.	1.6	22
57	Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB), and the integrin inhibitor cilengitide in patients (pts) with glioblastoma (GBM) without methylation of the MGMT gene promoter (ExCentric): Results of an Australian phase II clinical trial.. Journal of Clinical Oncology, 2014, 32, 2050-2050.	1.6	22
58	Epidermal growth factor receptorâ€tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung: A metaâ€analysis. Asia-Pacific Journal of Clinical Oncology, 2014, 10, 273-278.	1.1	21
59	Brain Metastases in Lung Cancers with Emerging Targetable Fusion Drivers. International Journal of Molecular Sciences, 2020, 21, 1416.	4.1	21
60	Anti-epidermal growth factor receptor therapy for glioblastoma in adults. The Cochrane Library, 2020, 2020, CD013238.	2.8	19
61	PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer. The Cochrane Library, 2021, 2021, CD011395.	2.8	19
62	Targeting Immunometabolism in Glioblastoma. Frontiers in Oncology, 2021, 11, 696402.	2.8	19
63	Immune Checkpoint Inhibitors for Brain Metastases. Current Oncology Reports, 2017, 19, 38.	4.0	18
64	Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. Clinical Cancer Research, 2022, 28, 585-593.	7.0	18
65	PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities. Cancers, 2022, 14, 1003.	3.7	18
66	Patterns of care in adult medulloblastoma: results of an international online survey. Journal of Neuro-Oncology, 2014, 120, 125-129.	2.9	17
67	A Discrete Choice Experiment to Examine the Preferences of Patients With Cancer and Their Willingness to Pay for Different Types of Health Care Appointments. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 311-319.	4.9	17
68	Evolving management of low grade glioma: No consensus amongst treating clinicians. Journal of Clinical Neuroscience, 2016, 23, 81-87.	1.5	17
69	Management of breast cancer brain metastases: A practical review. Breast, 2017, 31, 90-98.	2.2	16
70	ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours. BMC Cancer, 2016, 16, 339.	2.6	15
71	Geographic region, socioeconomic position and the utilisation of primary total joint replacement for hip or knee osteoarthritis across western Victoria: a cross-sectional multilevel study of the Australian Orthopaedic Association National Joint Replacement Registry. Archives of Osteoporosis, 2017, 12, 97.	2.4	15
72	What is the burden of proof for tumor mutational burden in gliomas?. Neuro-Oncology, 2021, 23, 17-22.	1.2	15

#	Article	IF	Citations
73	The epidemiology of hip fractures across western Victoria, Australia. Bone, 2018, 108, 1-9.	2.9	14
74	ATIM-49 (LTBK-01). AMG 596, A NOVEL ANTI-EGFRVIII BISPECIFIC T CELL ENGAGER (BITEÂ®) MOLECULE FOR THE TREATMENT OF GLIOBLASTOMA (GBM): PLANNED INTERIM ANALYSIS IN RECURRENT GBM (RGBM). Neuro-Oncology, 2019, 21, vi283-vi283.	1.2	14
75	Effect of treating glioblastoma with a cytokine inhibitor, ibudilast, in combination with temozolomide on survival in a patient-derived xenograft model.. Journal of Clinical Oncology, 2017, 35, 2062-2062.	1.6	14
76	New Approaches to Glioblastoma. Annual Review of Medicine, 2022, 73, 279-292.	12.2	14
77	The microenvironment of brain metastases from solid tumors. Neuro-Oncology Advances, 2021, 3, v121-v132.	0.7	14
78	A sociology of precisionâ€inâ€practice: The affective and temporal complexities of everyday clinical care. Sociology of Health and Illness, 2021, 43, 2178-2195.	2.1	14
79	Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma. Neuro-Oncology Advances, 2022, 4, .	0.7	14
80	Prioritization schema for immunotherapy clinical trials in glioblastoma. OncoImmunology, 2016, 5, e1145332.	4.6	13
81	Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response?. Clinical and Translational Oncology, 2017, 19, 273-278.	2.4	13
82	Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trialâ€"Clinical outcomes and molecular determinants of response. PLoS ONE, 2019, 14, e0210891.	2.5	13
83	Salting the Soil: Targeting the Microenvironment of Brain Metastases. Molecular Cancer Therapeutics, 2021, 20, 455-466.	4.1	13
84	Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-Î² and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma. Neuro-Oncology Advances, 2021, 3, vdab058.	0.7	13
85	Immune Microenvironment Landscape in CNS Tumors and Role in Responses to Immunotherapy. Cells, 2021, 10, 2032.	4.1	12
86	Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas. Clinical Cancer Research, 2022, 28, 2180-2195.	7.0	12
87	Primary systemic therapy in HER2-amplified breast cancer: a clinical review. Expert Review of Anticancer Therapy, 2012, 12, 1005-1013.	2.4	11
88	Ageing, Chronic Disease and Injury: A Study in Western Victoria (Australia). Journal of Public Health Research, 2016, 5, jphr.2016.678.	1.2	11
89	The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials. Lung Cancer, 2016, 102, 21-27.	2.0	11
90	Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-19 experience. Neuro-Oncology, 2021, 23, 1252-1260.	1.2	11

#	Article	IF	Citations
91	Abstract P1-19-03: JAVELIN PARP Medley, a phase 1b/2 study of avelumab plus talazoparib: Results from advanced breast cancer cohorts. , 2020, , .		11
92	A randomized phase II trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM).. Journal of Clinical Oncology, 2019, 37, 2011-2011.	1.6	11
93	For whom the T cells troll? Bispecific T-cell engagers in glioblastoma. , 2021, 9, e003679.		11
94	Molecular and clonal evolution in recurrent metastatic gliosarcoma. Journal of Physical Education and Sports Management, 2020, 6, a004671.	1.2	10
95	A Modified Nucleoside 6-Thio-2â€²-Deoxyguanosine Exhibits Antitumor Activity in Gliomas. Clinical Cancer Research, 2021, 27, 6800-6814.	7.0	10
96	A validated integrated clinical and molecular glioblastoma long-term survival-predictive nomogram. Neuro-Oncology Advances, 2021, 3, vdaa146.	0.7	10
97	Evaluating the role of magnetic resonance imaging postâ€neoadjuvant therapy for breast cancer in the <scp>NEONAB</scp> trial. Internal Medicine Journal, 2018, 48, 699-705.	0.8	9
98	Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study. Clinical Colorectal Cancer, 2018, 17, 313-319.	2.3	9
99	Mapping Cancer incidence across Western Victoria: the association with age, accessibility, and socioeconomic status among men and women. BMC Cancer, 2019, 19, 892.	2.6	9
100	Immune thrombocytopenic purpura (ITP) and breast cancer. Does adjuvant therapy for breast cancer improve platelet counts in ITP?. Annals of Oncology, 2009, 20, 1282-1283.	1.2	8
101	Brain metastases in breast cancer. Expert Review of Anticancer Therapy, 2014, 14, 173-183.	2.4	8
102	Patientâ€reported experience of the impact and burden of neuroendocrine tumors: Oceania patient results from a large global survey. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 256-263.	1.1	8
103	A randomized phase 2, single-blind study of temozolomide (TMZ) and radiotherapy (RT) combined with nivolumab or placebo (PBO) in newly diagnosed adult patients (pts) with tumor O6-methylguanine DNA methyltransferase (MGMT)-methylated glioblastoma (GBM)â€"CheckMate-548. Annals of Oncology, 2016, 27, vi113.	1.2	7
104	The role of large volume re-irradiation with Bevacizumab in chemorefractory high grade glioma. Clinical and Translational Radiation Oncology, 2020, 22, 33-39.	1.7	7
105	Experiencing the SARS-CoV-2 Pandemic Whilst Living With Cancer. Qualitative Health Research, 2022, 32, 426-439.	2.1	7
106	Holding back the sea: the role for maintenance chemotherapy in metastatic breast cancer. Breast Cancer Research and Treatment, 2010, 122, 177-179.	2.5	6
107	Understanding the Revised Fourth Edition of the World Health Organization Classification of Tumours of the Central Nervous System (2016) for Clinical Decision-making: A Guide for Oncologists Managing Patients with Glioma. Clinical Oncology, 2018, 30, 556-562.	1.4	6
108	Influence of molecular classification in anaplastic glioma for determining outcome and future approach to management. Journal of Medical Imaging and Radiation Oncology, 2019, 63, 272-280.	1.8	6

#	Article	IF	Citations
109	Pattern of failure in anaplastic glioma patients with an IDH1/2 mutation. Strahlentherapie Und Onkologie, 2020, 196, 31-39.	2.0	6
110	The efficacy and safety of sunitinib in patients with advanced well-differentiated pancreatic neuroendocrine tumors.. Journal of Clinical Oncology, 2017, 35, 380-380.	1.6	6
111	Objective radiological disease control with Sandostatin monotherapy in metastatic neuroendocrine tumours. Internal Medicine Journal, 2010, 40, 453-458.	0.8	5
112	Association between area-level socioeconomic status, accessibility and diabetes-related hospitalisations: a cross-sectional analysis of data from Western Victoria, Australia. BMJ Open, 2019, 9, e026880.	1.9	5
113	Management of glioblastoma: an Australian perspective. Chinese Clinical Oncology, 2021, 10, 42-42.	1.2	5
114	Genomic evaluation of tumor mutational burden-high (TMB-H) versus TMB-low (TMB-L) metastatic breast cancer to reveal unique mutational features.. Journal of Clinical Oncology, 2021, 39, 1091-1091.	1.6	5
115	GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.. Journal of Clinical Oncology, 2020, 38, TPS2579-TPS2579.	1.6	5
116	Low tumor mutational burden and immunotherapy in gliomas. Trends in Cancer, 2022, 8, 345-346.	7.4	5
117	A phase 1 trial of D2C7-it in combination with an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma (MG).. Journal of Clinical Oncology, 2022, 40, e14015-e14015.	1.6	5
118	Poly(ADP-ribose) polymerase inhibitors in breast cancer and other tumors: advances and challenges. Clinical Investigation, 2011, 1, 1545-1554.	0.0	4
119	Colorectal cancer: is the incidence rising in young Iraqi patients?. Asia-Pacific Journal of Clinical Oncology, 2012, 8, 380-381.	1.1	4
120	Neuroendocrine neoplasms of the GI tract: the role of cytotoxic chemotherapy. Expert Review of Anticancer Therapy, 2013, 13, 451-459.	2.4	4
121	Phase I study evaluating safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-428, first-in-class mesothelin (MSLN)-CD40 bispecific, in patients (pts) with advanced solid tumours. Annals of Oncology, 2019, 30, v498-v499.	1.2	4
122	Anti-epidermal growth factor receptor therapy for glioblastoma in adults. The Cochrane Library, 2019, , .	2.8	4
123	The epidemiology of emergency presentations for falls from height across Western Victoria, Australia. Australasian Emergency Care, 2020, 23, 119-125.	1.5	4
124	Barriers and potential solutions to international collaboration in neuroâ€•oncology clinical trials: Challenges from the Australian perspective. Asia-Pacific Journal of Clinical Oncology, 2022, 18, 259-266.	1.1	4
125	Clinical Trials with Biologic Primary Endpoints in Immuno-oncology: Concepts and Usage. Clinical Cancer Research, 2022, 28, 13-22.	7.0	4
126	CTIM-21. PEPTIDE VACCINE DIRECTED TO CMV pp65 FOR TREATMENT OF RECURRENT MALIGNANT GLIOMA AND MEDULLOBLASTOMA IN CHILDREN AND YOUNG ADULTS: PRELIMINARY RESULTS OF A PHASE I TRIAL. Neuro-Oncology, 2020, 22, ii37-ii37.	1.2	4

#	Article	IF	Citations
127	Use of targeted therapy in cancer patients in the end-of-life period.. Journal of Clinical Oncology, 2014, 32, 129-129.	1.6	4
128	Retrospective analysis of cancer survival across South-Western Victoria in Australia. Australian Journal of Rural Health, 2016, 24, 79-84.	1.5	3
129	Traveling With Cancer: A Guide for Oncologists in the Modern World. Journal of Global Oncology, 2019, 5, 1-10.	0.5	3
130	Reflecting on survivorship outcomes to aid initial decision making in patients treated for IDHâ€mutated anaplastic glioma. Cancer, 2019, 125, 3457-3466.	4.1	3
131	Revision joint replacement surgeries of the hip and knee across geographic region and socioeconomic status in the western region of Victoria: a cross-sectional multilevel analysis of registry data. BMC Musculoskeletal Disorders, 2019, 20, 300.	1.9	3
132	The role of immunotherapy in fusion-driven lung cancer. Expert Review of Anticancer Therapy, 2021, 21, 461-464.	2.4	3
133	A phase 1 dose-escalation study of a PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies.. Journal of Clinical Oncology, 2021, 39, 2585-2585.	1.6	3
134	Defining the Supportive Care Needs and Psychological Morbidity of Patients With Functioning Versus Nonfunctioning Neuroendocrine Tumors: Protocol for a Phase 1 Trial of a Nurse-Led Online and Phone-Based Intervention. JMIR Research Protocols, 2019, 8, e14361.	1.0	3
135	CTIM-23. A PHASE 1 TRIAL OF D2C7-IT IN COMBINATION WITH ATEZOLIZUMAB IN RECURRENT WHO GRADE IV MALIGNANT GLIOMA (MG). Neuro-Oncology, 2020, 22, ii38-ii38.	1.2	3
136	GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.. Journal of Clinical Oncology, 2022, 40, TPS2078-TPS2078.	1.6	3
137	Hormonal Resistance in Breast Cancer: Evolving Treatment Strategies. Current Breast Cancer Reports, 2012, 4, 66-74.	1.0	2
138	Neuroendocrine tumors of the gastrointestinal tract and the role of cytotoxic chemotherapy. Expert Review of Anticancer Therapy, 2016, 16, 391-401.	2.4	2
139	Use of targeted therapy in cancer patients in the end-of-life period: results from an Australian centre. Supportive Care in Cancer, 2016, 24, 3023-8.	2.2	2
140	ATIM-16. PHASE 1 STUDY RESULTS OF M7824 (MSB0011359C), A BIFUNCTIONAL FUSION PROTEIN TARGETING TGF- AND PD-L1, AMONG PATIENTS WITH RECURRENT GLIOBLASTOMA (rGBM). Neuro-Oncology, 2018, 20, vi4-vi4.	1.2	2
141	EPID-13. ANTI-ANGIOGENIC THERAPY FOR HIGH-GRADE GLIOMA: A META-ANALYSIS. Neuro-Oncology, 2018, 20, vi82-vi83.	1.2	2
142	The epidemiology of emergency presentations for falls across Western Victoria, Australia. Australasian Emergency Care, 2019, 22, 206-215.	1.5	2
143	Driving innovation through collaboration: development of clinical annotation datasets for brain cancer biobanking. Neuro-Oncology Practice, 2020, 7, 31-37.	1.6	2
144	GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.. Journal of Clinical Oncology, 2021, 39, TPS2074-TPS2074.	1.6	2

#	Article	IF	Citations
145	Reply to: â€˜Real-world prevalence across 159Â872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.â€™ by D. Fabrizio etÂal.. Annals of Oncology, 2021, 32, 1194-1197.	1.2	2
146	ICE CREAM: Irinotecan cetuximab evaluation and the cetuximab response evaluation among patients with G13D mutation.. Journal of Clinical Oncology, 2013, 31, TPS3649-TPS3649.	1.6	2
147	Abstract 3777: Combining VELIPARIB (ABT-888) with temozolomide shows strong synergy when treating temozolomide-resistant and recurrent GBM cell lines. , 2014, , .		2
148	Alternative targeted therapy for early Her2 positive breast cancer. Gland Surgery, 2013, 2, 42-5.	1.1	2
149	CTIM-10. REPRODUCIBILITY OF CLINICAL TRIALS USING CMV-TARGETED DENDRITIC CELL VACCINES IN PATIENTS WITH GLIOBLASTOMA. Neuro-Oncology, 2021, 23, vi51-vi51.	1.2	2
150	LUMOS - Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS at relapse: Protocol for a pilot study. BMJ Open, 2021, 11, e054075.	1.9	2
151	Cardiac toxicity from sunitinib: Do we need to be more vigilant?. Asia-Pacific Journal of Clinical Oncology, 2009, 5, 217-218.	1.1	1
152	16. Primary choriocarcinoma of the colon â€“ a case report. Pathology, 2010, 42, S85-S86.	0.6	1
153	Neurological Complications of Non-Hodgkin Lymphoma. , 2012, , 267-285.		1
154	SURG-06. OUTCOMES OF SECOND SURGERY FOR RECURRENT GLIOBLASTOMA MULTIFORME: AÂRETROSPECTIVE CASE CONTROL STUDY. Neuro-Oncology, 2016, 18, vi192-vi192.	1.2	1
155	RBTT-07. NUTMEG: A RANDOMISED PHASE II STUDY OF NIVOLUMAB AND TEMOZOLOMIDE (TMZ) VS TMZ ALONE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM): TRIAL IN PROGRESS. Neuro-Oncology, 2018, 20, vi235-vi235.	1.2	1
156	Optimising Outcomes for Glioblastoma through Subspecialisation in a Regional Cancer Centre. Brain Sciences, 2018, 8, 186.	2.3	1
157	EPID-23. PURSUIT OF AN INTERNATIONAL LANGUAGE OF GLIOMA RESEARCH: COMMON DATA ELEMENTS FOR THE LONGITUDINAL STUDY OF ADULT MALIGNANT GLIOMA. Neuro-Oncology, 2019, 21, vi79-vi79.	1.2	1
158	ACTR-24. A RANDOMIZED PHASE II TRIAL OF VELIPARIB (V), RADIOTHERAPY (RT) AND TEMOZOLOMIDE (TMZ) IN PATIENTS (PTS) WITH UNMETHYLATED MGMT (uMGMT) GLIOBLASTOMA (GBM): THE VERTU STUDY. Neuro-Oncology, 2019, 21, vi18-vi18.	1.2	1
159	mRNA profiling of a well-differentiated G1 pancreatic NET correlates with immunohistochemistry profile: a case report. BMC Gastroenterology, 2021, 21, 194.	2.0	1
160	Results of the Quad wild type arm of the AGITG ICECREAM study: A randomised phase II study of cetuximab alone or in combination with irinotecan in patients with refractory metastatic colorectal cancer with no mutations in KRAS, NRAS, BRAF or PIK3CA.. Journal of Clinical Oncology, 2017, 35, 3572-3572.	1.6	1
161	A randomized phase 2 trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM): Feasibility and safety outcomes (the VERTU) Tj ETQq1 1 0.784314 rgBT /Ov	1.6	1
162	Health-related quality of life (HRQL) in VERTU: A randomized phase II trial of veliparib (V), radiotherapy (RT), and temozolomide (TMZ) for newly diagnosed MGMT unmethylated (uMGMT) glioblastoma (GBM).. Journal of Clinical Oncology, 2019, 37, 2042-2042.	1.6	1

#	Article	IF	Citations
163	Abstract A12: Genomically unstable glioblastoma are sensitive to Parp inhibition. , 2015, , .		1
164	Anti-angiogenic therapy for lung cancer. The Cochrane Library, 0, , .	2.8	0
165	Poly(ADP-Ribose) Polymerase (PARP) Inhibitors for locally advanced or metastatic breast cancer. The Cochrane Library, 0, , .	2.8	0
166	ATPS-54GENOMICALLY UNSTABLE GLIOBLASTOMA (U-GBM) SHOW EXQUISITE SENSITIVITY TO PARP INHIBITION. Neuro-Oncology, 2015, 17, v30.2-v30.	1.2	0
167	Reply to Dr Altundag from the authors of â€˜Management of breast cancer brain metastases; a practical reviewâ€™. Breast, 2017, 34, 133.	2.2	0
168	CMET-09. PAN-CANCER PROFILES OF BRAIN METASTASES: PRIORITIZATION OF THERAPEUTIC TARGETS. Neuro-Oncology, 2017, 19, vi40-vi41.	1.2	0
169	P01.20 Treatment of recurrent glioblastoma with the cytokine inhibitor, ibudilast in combination with temozolomide. Neuro-Oncology, 2017, 19, iii27-iii27.	1.2	0
170	P01.035 Nivolumab and Temozolomide (TMZ) vs TMZ alone in newly diagnosed elderly patients (pts) with Glioblastoma (GBM) (NUTMEG): Trial in progress. Neuro-Oncology, 2018, 20, iii236-iii236.	1.2	0
171	ACTR-29. A SERIES OF PATIENTS (PTS) WITH RECURRENT GBM (rGBM) TREATED WITH ABT-414, BEVACIZUMAB (BEV) AND CCNU. Neuro-Oncology, 2019, 21, vi19-vi19.	1.2	0
172	COMP-15. MOLECULAR AND CLONAL EVOLUTION IN RECURRENT METASTATIC GLIOSARCOMA. Neuro-Oncology, 2019, 21, vi64-vi64.	1.2	0
173	The Epidemiology of Joint Replacements Across Western Victoria, Australia: a Cross-sectional Study. SN Comprehensive Clinical Medicine, 2019, 1, 1038-1047.	0.6	0
174	Immunotherapy for glioblastoma as a means to overcome resistance to standard therapy. , 2021, , 635-665.		0
175	Intra-aortic metastases or intra-arterial thrombus?. International Journal of Case Reports and Images, 2013, 4, 368.	0.0	0
176	A meta-analysis of antiangiogenic therapy for glioblastoma (GBM).. Journal of Clinical Oncology, 2014, 32, 2047-2047.	1.6	0
177	Prospective evaluation of KRAS, NRAS, BRAF, and PI3KCA mutation screening for patient enrolment in AGITG ICECREAM (Irinotecan Cetuximab Evaluation and the Cetuximab Response) Tj ETQq1 1 0.784314 rgBT /Overlock 10 of Clinical Oncology, 2014, 32, e14536-e14536.	1.6	0
178	Tailored neoadjuvant epirubicin and cyclophosphamide and nanoparticle albumin bound (nab)-paclitaxel for newly diagnosed breast cancer.. Journal of Clinical Oncology, 2014, 32, TPS1135-TPS1135.	1.6	0
179	Mutational analysis of matched initial and recurrent TP53 WT primary GBM.. Journal of Clinical Oncology, 2015, 33, 2043-2043.	1.6	0
180	Identification of glioblastoma patients who stand to benefit from PARP inhibitor therapy.. Journal of Clinical Oncology, 2015, 33, 2071-2071.	1.6	0

#	Article	IF	Citations
181	A discrete choice experiment to examine the preferences of patients with cancer and their willingness to pay for different types of health care appointments.. Journal of Clinical Oncology, 2015, 33, 6527-6527.	1.6	0
182	Tailored neoadjuvant epirubicin and cyclophosphamide (EC) and nanoparticle albumin-bound paclitaxel (nab-P) in breast cancer.. Journal of Clinical Oncology, 2016, 34, e12515-e12515.	1.6	0
183	AGITG nabnec: A randomised phase II study of nab-paclitaxel in combination with carboplatin as first line treatment of gastrointestinal neuroendocrine carcinomas.. Journal of Clinical Oncology, 2018, 36, TPS548-TPS548.	1.6	0
184	Poly(ADP-Ribose) Polymerase Inhibitors (PARPi) for patients (pts) with locally advanced or metastatic breast cancer (BC): A meta-analysis.. Journal of Clinical Oncology, 2018, 36, 1076-1076.	1.6	0
185	INNV-08. LOW AND INTERMEDIATE GRADE GLIOMA UMBRELLA STUDY OF MOLECULAR GUIDED THERAPIES (LUMOS) STUDY. Neuro-Oncology, 2021, 23, vi106-vi107.	1.2	0
186	EPCO-09. LONGITUDINAL ANALYSIS OF DIFFUSE GLIOMA REVEALS CELL STATE DYNAMICS AT RECURRENCE ASSOCIATED WITH CHANGES IN GENETICS AND THE MICROENVIRONMENT. Neuro-Oncology, 2021, 23, vi3-vi3.	1.2	0
187	INNV-31. NEURO-ONCOLOGY OUTPATIENT SATISFACTION IS MAINTAINED IN THE ERA OF COVID-19 TELEMEDICINE. Neuro-Oncology, 2021, 23, vi112-vi112.	1.2	0
188	QOLP-28. COMPARING KNOWLEDGE OF AND BELIEFS ABOUT PALLIATIVE CARE AMONG NEURO-ONCOLOGY PATIENTS, CAREGIVERS, PROVIDERS AND A NATIONALLY-REPRESENTATIVE U.S. SAMPLE. Neuro-Oncology, 2021, 23, vi189-vi189.	1.2	0
189	EXTH-82. T CELL HITCHHIKING AS A MECHANISM OF DRUG DELIVERY TO THE BRAIN. Neuro-Oncology, 2021, 23, vi182-vi182.	1.2	0
190	RTID-11. GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii195-ii196.	1.2	0
191	COVD-25. THE PARADOXICAL EFFECTS OF COVID-19 ON CANCER CARE IN THE NEURO-ONCOLOGY SETTING. Neuro-Oncology, 2020, 22, ii26-ii26.	1.2	0
192	BIOM-17. BRAF MUTATION IS AN EARLY EVENT IN THE EVOLUTION OF A SUBSET OF GLIOBLASTOMAS AND IS ASSOCIATED WITH INCREASED PD-L1 EXPRESSION. Neuro-Oncology, 2020, 22, ii5-ii5.	1.2	0
193	Patterns of care in adult histone mutant gliomas: results of an international survey. Neuro-Oncology Practice, 0, , .	1.6	0
194	Characterization of industry relationships in oncology.. Journal of Clinical Oncology, 2022, 40, 11025-11025.	1.6	0
195	A phase 0/surgical window-of-opportunity study in progress, evaluating evolocumab in patients with high-grade glioma or glioblastoma.. Journal of Clinical Oncology, 2022, 40, TPS2076-TPS2076.	1.6	0